39.76 USD
↗ 1.57 (4.11%)AT CLOSE (11:59 AM EDT)
Edgewise Therapeutics, Inc. Common Stock
EWTXNASDAQ • USD
38.93
↘ 0.83 (2.09%)
POST MARKET (AS OF 05:16 PM EDT)
Post Market
AS OF 05:16 PM EDT
38.93
↘ 0.83 (2.09%)
Market: OPEN
Edgewise Therapeutics, Inc. Common Stock (EWTX) trades at $40.84 per share. The technical outlook is "Buy" and the fundamental picture shows "Neutral". Key drivers include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. Furthermore, EWTX is currently richly valued, trading at a premium to sector peers across key valuation metrics.
Technical & fundamental data as of Jul 17, 2026.
Open?$38.60
High?$40.40
Low?$37.25
Prev. Close?$38.19
Volume?744.7K
Avg. Volume?1.6M
VWAP?$39.75
Rel. Volume?0.48x
Bid / Ask
Bid?$32.37 × 100
Ask?$45.79 × 100
Spread?$13.42
Midpoint?$39.08
Valuation & Ratios
Market Cap?4.1B
Shares Out?107.6M
Float?73.5M
Float %?69.5%
P/E Ratio?N/A
P/B Ratio?8.33
EPS?-$1.64
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
Employees
154
Market Cap
4.1B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2021-03-26
Address
1715 38TH ST
BOULDER, CO 80301
Phone: 720-262-7002
BOULDER, CO 80301
Phone: 720-262-7002
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?▲ Bullish(+1/3)
MA Alignment?Golden Alignment
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?100
Momentum?50
Short Sent.?35
Piotroski F-Score?0/9Weak
Altman Z-Score?95.62Safe
Confidence?49%Low
Short InterestHigh
Short % of Float?14.27%High
Short Interest?10.5M
Days to Cover?5.0
Free Float73.5M
Avg Daily Volume2.1M
Settlement Date2026-06-30
Financial Health
Current Ratio?22.61Strong
Quick Ratio?22.61Strong
Cash Ratio?1.47Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score67/100
P/E?N/A▾
P/B?8.33HIGH▾
Peers100
S&P23
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-20.6CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-35.7%WEAK▾
S&P5
ROA?-33.9%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-148965000
Enterprise Value?$4.1B
Fundamentals ratios updated end of day